Differences in efficacy and toxicity in relation to genetic polymorphisms of the cytochrome P450 2C8 gene after chemotherapy in epithelial ovarian cancer

Purpose of investigation: To survey genetic polymorphisms in the promoter region of the cytochrome P450 2C8 family gene (CYP2C8) in patients with epithelial ovarian cancer, and to determine whether the frequency of genetic polymorphisms and haplotypes in CYP2C8 are associated with efficacy and toxicity of anticancer drugs. Materials and Methods: The authors enrolled 43 patients diagnosed with epithelial ovarian cancer. They performed direct sequencing PCR using specific primers to detect single nucleotide polymorphisms (SNPs). They analyzed the efficacy and toxicity of chemotherapy in relation to SNP allele and haplotype patterns in patients. Results: The mutant alleles CYP2C8^*1D (-411T>C), CYP2C8^*1C (-370T>G), and CYP2C8^*1B (-271C>A) were found in the patient group, with an allele frequency of 0.37, 0.32, and 0.09, respectively. Of the 35 patients with advanced epithelial ovarian cancer, the CYP2C8^*1D mutation group had a significantly shorter disease-free interval after treatment (p = 0.020). Conclusions: CYP2C8^*1D mutation group had poorer prognosis and earlier onset of neurotoxicity.

CYP2C8; Genetic polymorphism; Ovarian cancer

[1] Nebert D.W., Gonzalez F.J.: “P450 genes: structure, evolution, and regulation”. Annu. Rev. Biochem., 1987, 56, 945.

[2] Cresteil T., Monsarrat B., Alvinerie P., Treluyer J.M., Vieira I., Wright M.: “Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation”. Cancer. Res., 1994, 54, 386.

[3] de Morais S.M., Wilkinson G.R., Blaisdell J., Nakamura K., Meyer U.A., Goldstein J.A.: “The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans”. J. Biol. Chem., 1994, 269, 15419.

[4] Goldstein J.A.: “Clinical relevance of genetic polymorphisms in the human CYP2C subfamily”. Br. J. Clin. Pharmacol., 2001, 52, 349.

[5] Goldstein J.A., de Morais S.M.: “Biochemistry and molecular biology of the human CYP2C subfamily”. Pharmacogenetics., 1994, 4, 285.

[6] Sullivan-Klose T.H., Ghanayem B.I., Bell D.A., Zhang Z.Y., Kaminsky L.S., Shenfield G.M., et al.: “The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism”. Pharmacogenetics., 1996, 6, 341.

[7] McGiff J.C.: “Cytochrome P-450 metabolism of arachidonic acid”. Annu. Rev. Pharmacol. Toxicol., 1991, 31, 339.

[8] Dai D., Zeldin D.C., Blaisdell J.A., Chanas B., Coulter S.J., Ghanayem B.I., et al.: “Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid”. Pharmacogenetics., 2001, 11, 597.

[9] Sugawara T., Nomura E., Sagawa T., Sakuragi N., Fujimoto S.: “CYP1A1 polymorphism and risk of gynecologic malignancy in Japan”. Int. J. Gynecol. Cancer., 2003, 13, 785.

[10] Cho J., Suh Y., Lee J., Yi S., Hong K.: “Identification of polymorphisms in human CYP2C8 gene by two-dimensional gel scanning in healthy Koreans”. Clin. Pharmacol. Ther., 2003, 2, 41.

[11] Oscarson M.: “Homepage of the cytochrome P450 (CYP) allele nomenclature committee”. February 1, 2001. Available at: http://www.imm.ki.se/CYPalleles/. Accessed on September 1, 2003.

[12] Memarzadeh S., Berek J.S.: “Advances in the management of epithelial ovarian cancer”. J. Reprod. Med., 2001, 46, 621.

[13] Berek J.S., Bertlesen K., du Bois A., Brady M.F., Carmichael J., Eisenhauer E.A., et al.: “Advanced epithelial ovarian cancer: 1998 consensus statements”. Ann. Oncol., 1999, 10, 87.

[14] Balkwill F., Bast R.C., Berek J.S., Brady M.F., Carmichael J., Eisen- hauer E.A., et al.: “Current research and treatment for epithelial ovarian cancer. A position paper from the Helene Harris Memorial Trust”. Eur. J. Cancer., 2003, 39, 1818.

[15] McGuire W.P., Hoskins W.J., Brady M.F., Kucera P.R., Partridge E.E., Look K.Y., et al.: “Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer”. N. Engl. J. Med., 1996, 334, 1.

[16] “Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group”. BMJ, 1991, 303, 884.

[17] Iyer L., Das S., Janisch L., Janisch L., Wen M., Ramirez J., Karrison T., et al.: “UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity”. Pharmacogenomics. J., 2002, 2, 43.

[18] Shimada T., Yamazaki H., Mimura M., Inui Y., Guengerich F.P.: “Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians”. J. Pharmacol. Exp. Ther., 1994, 270, 414.

[19] Johansson I., Lundqvist E., Bertilsson L., Dahl M.L., Sjogvist F., Ingelman-Sundberg M.: “Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine”. Proc. Natl. Acad. Sci. USA., 1993, 90, 11825.

[20] Gaedigk A., Gotschall R.R., Forbes N.S., Simon S.D., Kearns G.L., Leeder J.S.: “Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data”. Pharmacogenetics., 1998, 9, 669.

[21] Gaedigk A., Bradford L.D., Marcucci K.A., Leeder J.S.: “Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans”. Clin. Pharmacol. Ther., 2002, 72, 76.

[22] Tateishi T., Chida M., Ariyoshi N., Mizorogi Y., Kamataki T., Kobayashi S.: “Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population”. Clin. Pharmacol. Ther., 1999, 65, 570.

[23] Mathijssen R.H., van Alphen R.J., Verweij J., Loos W.J., Nooter K., Stoter G., et al.: “Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)”. Clin. Cancer. Res., 2001, 7, 2182.

[24] Mathijssen R.H., Verweij J., de Bruijn P., Loos W.J., Sparreboom A.: “Effects of St. John’s wort on irinotecan metabolism”. J. Natl. Cancer. Inst., 2002, 94, 1247.

[25] Kumar G., Ray S., Walle T., Huang Y., Willingham M., Self S., et al.: “Comparative in vitro cytotoxic effects of taxol and its major human metabolite 6 alpha-hydroxytaxol”. Cancer. Chemother. Pharmacol. 1995, 36, 129.

[26] Walle T., Walle U.K., Kumar G.N., Bhalla K.N.: “Taxol metabolism and disposition in cancer patients”. Drug. Metab. Dispos., 1995, 23, 506.

[27] Wani M.C., Taylor H.L., Wall M.E., Coggon P., McPhail A.T.: “Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia”. J. Am. Chem. Soc., 1971, 93, 2325.

[28] Lasker J.M., Chen W.B., Wolf I., Bloswick B.P., Wilson P.D., Powell P.K.: “Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11”. J. Biol. Chem., 2000, 275, 4118.

[29] Luo G., Zeldin D.C., Blaisdell J.A., Hodgson E., Goldstein J.A.: “Cloning and expression of murine CYP2Cs and their ability to metabolize arachidonic acid”. Arch. Biochem. Biophys., 1998, 357, 45.

[30] Ojeda S.R., Urbanski H.F., Junier M.P., Capdevila J.: “The role of arachidonic acid and its metabolites in the release of neuropeptides”. Ann. NY. Acad. Sci., 1989, 559, 192.

[31] Node K., Huo Y., Ruan X., Yang B., Spiecker M., Ley K., et al.: “Antiinflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids”. Science., 1999, 285, 1276.

[32] Sonnichsen D.S., Liu Q., Schuetz E.G., Schuetz J.D., Pappo A., Relling M.V.: “Variability in human cytochrome P450 paclitaxel metabolism”. J. Pharmacol. Exp. Ther., 1995, 275, 566.

[33] Bahadur N., Leathart J.B., Mutch E., Steimel-Crespi D., Dunn S.A., Gilissen R., et al.: “CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes”. Biochem. Pharmacol., 2002, 64, 1579.

[34] Soyama A., Saito Y., Komammura K., Ueno K., Kamakura S., Ozawa S., et al.: “Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift”. Drug. Metab. Pharmacokinet., 2002, 17, 374.

[35] Soyama A., Hanioka N., Saito Y., Murayama N., Ando M., Ozawa S., et al.: “Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A”. Pharmacol. Toxicol., 2002, 91, 174.